International journal of clinical practice
-
The new coronavirus (SARS-COV-2) that emerged at the end of 2019 was stated in China and infected millions of people around the world, with the highest spread rate amongst humans compared with other coronaviruses. This paper aimed to review and analyse the published studies about COVID-19 diagnosis, prevention, and treatment. ⋯ Nature of COVID-19 is still not very clear, however, management of the condition is similar to the previous attacks of coronaviruses.
-
Int. J. Clin. Pract. · May 2021
Meta AnalysisEfficacy and safety of OM-85 in pediatric recurrent respiratory tract infections which could have a possible protective effect in COVID-19 pandemic: A meta-analysis.
The OM-85 (Broncho-Vaxom) consumption has drawn considerable attention in the prevention of recurrent respiratory tract infections. However, it has been reported that the relationship between OM-85 consumption and recurrent respiratory tract infections is variable. This meta-analysis was performed to evaluate this relationship. ⋯ The impact of OM-85 consumption on recurrent respiratory tract infections may have a great effect as a tool to improve subjects' immunity against recurrent respiratory tract infections, which could be helpful in crucial situations, eg, COVID-19 pandemic. OM-85 non-consumers had an independent risk relationship with recurrent respiratory tract infections. This relationship forces us to recommend OM-85 consumption with those with a high risk of recurrent respiratory tract infections to avoid any possible complications.
-
Int. J. Clin. Pract. · May 2021
Randomized Controlled TrialVibegron Improves Quality-of-Life Measures in Patients With Overactive Bladder: Patient-Reported Outcomes From the EMPOWUR Study.
Quality of life (QOL) can be significantly impacted by symptoms of overactive bladder (OAB). Vibegron is a highly selective β3 -adrenergic receptor agonist that showed efficacy in treatment of symptoms of OAB in the randomised, double-blind, placebo- and active-controlled phase 3 EMPOWUR trial. Here we report patient-reported QOL outcomes from the EMPOWUR trial. ⋯ ClinicalTrials.gov identifier number NCT03492281.
-
Int. J. Clin. Pract. · May 2021
Randomized Controlled TrialEffects of Adjuvant Low-Dye Kinesio Taping, Adjuvant Sham Taping, or Extracorporeal Shockwave Therapy Alone in Plantar Fasciitis: A Randomized Double-Blind Controlled Trial.
Extracorporeal shockwave therapy (ESWT) is known as one of the most effective treatment methods in plantar fasciitis (PF). Low-dye taping, which is the most preferred method of banding treatments, provides an analgesic effect by correcting biomechanics. It was aimed to compare the efficacy of adjuvant low-dye kinesio-taping (KT), sham-taping, or ESWT alone in PF. ⋯ The study was registered at the U.S. National Institutes of Health (ClinicalTrials.gov) (NCT03904966).
-
Int. J. Clin. Pract. · May 2021
Treatment Management of COVID-19 Positive Patients with Renal Colic Secondary to Distal Ureteral Stone.
In this study, we aimed to contribute to the literature by sharing and evaluating the clinical characteristics and our treatment and follow-up approaches in patients in the COVID-19 positive treatment process who had presented to our hospital's emergency department with a distal ureteral stone and to examine the effects of the pandemic and disease in this group of patients. ⋯ In most COVID-19 infected patients with renal colic and a distal ureteral stone, results can be obtained using MET. Patients with a distal ureteral stone and persistent renal colic can be safely and effectively treated by endoscopic ureteral stone treatment after taking necessary precautions. Prospective, randomised, and controlled studies are required on this subject.